<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642239</url>
  </required_header>
  <id_info>
    <org_study_id>CMNa-ESO-01-2007</org_study_id>
    <nct_id>NCT00642239</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Luye Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Luye Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentered clinical trial is going to find out the radio-sensitization action of
      sodium glycididazole in radiochemotherapy for esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal cancer is one of the most frequent causes of cancer death in the world. The most
      common type of esophageal cancer is squamous cell carcinoma (SCC) in China. Although
      concurrent radiochemotherapy is recommended as the standard treatment for advanced esophageal
      carcinoma, the local failure still reaches up to 44%-54%.

      Sodium Glycididazole(CMNa) is a radiosensitive drug for hypoxic tumor cells. Clinical trials
      showed that CMNa can improve local control rate and survival rate of esophageal cancer. This
      study is going to confirm the efficacy and safety of CMNa in concurrent radiochemotherapy of
      radiotherapy and 5-FU+DDP for esophageal squamous carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumour local control rate</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival rate</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Esophageal Carcinoma</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Concurrent radiochemotherapy and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent radiochemotherapy and Sodium Glycididazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Glycididazole</intervention_name>
    <description>Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CMNa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written informed consent

          -  photographically and histologically proven thoracic esophageal squamous carcinoma

          -  stages 2a-3, and stage 4 with only supraclavicular lymph nodes metastasis defined by
             AJCC(2002)

          -  radiochemotherapy indication

          -  measurable tumor

          -  adequate hematologic, hepatic and renal function

          -  Karnofsky performance status â‰¥70

          -  age more than 18years and less than 70 years

        Exclusion Criteria:

          -  pregnancy and lactation

          -  significant neurologic disease

          -  severe liver and renal malfunction,and Significant medical illness

          -  previous chemotherapy, radiotherapy or immunotherapy

          -  esophagus hemorrhage and esophagus perforation features
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lvhua Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital, Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lvhua Wang, Doctor</last_name>
    <phone>86-10-87788503</phone>
    <email>wlhwq@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Liang, Doctor</last_name>
    <phone>86-10-87788503</phone>
    <email>lj139117@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Xu, Doctor</last_name>
      <phone>8610-88196170</phone>
      <email>fangliaoxubo@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Bo Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mengzhong Liu, Doctor</last_name>
      <phone>8620-83743371</phone>
      <email>lmz1955@163.com</email>
    </contact>
    <investigator>
      <last_name>Mengzhong Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengying Wang, Doctor</last_name>
      <phone>8621-64160820</phone>
    </contact>
    <investigator>
      <last_name>FengYing Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lvhua Wang, Doctor</last_name>
      <phone>86-10-87788503</phone>
      <email>wlhwq@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Jun Liang, Doctor</last_name>
      <phone>86-10-87788503</phone>
      <email>lj139117@yahoo.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Lvhua Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>May 13, 2008</last_update_submitted>
  <last_update_submitted_qc>May 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lvhua Wang/Professor</name_title>
    <organization>Cancer Hospital of Chinese Academy of Medical Sciences</organization>
  </responsible_party>
  <keyword>Sodium Glycididazole, Radiochemotherapy, Esophageal Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

